AzTrials
AzTrials

Attention Deficit-Hyperactivity DisorderTLR;NCT04038073

TLR Polymorphism, ASO and Beta-hemolytic Group A Streptococcus Infections in ADHD: an Observational Study

An observational study of Attention Deficit-Hyperactivity Disorder, run by University of Turin, Italy at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of this observational cross-sectional study is to evaluate the streptococcal infection (clinical history, ASLO title and anti-DNAse title B) and autoimmunity (ABGA antibodies) in a sample of 100 adult patients diagnosed with ADHD (ie in patients in whom the disorder is permanent). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Attention Deficit-Hyperactivity Disorder
What is being tested?
Antistreptolysin O Test, Anti-Deoxyribonuclease B and TLR, MyD88, IRAK-4 polymorphism
How many people
100 participants
Where
1 siteItaly
Study dates
3 Jun 2019to 1 Dec 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Participants with ADHD disgnosis (according to DSM-5 criteria) will be recruited for a single blood sample.

Who may be able to join

  • diagnosis of ADHD according to DSM-5 criteria

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Francesco Oliva contact

3335613155

francesco.oliva@unito.it

Italy1 site, 1 recruiting
  • AOU San Luigi Gonzaga di Orbassano

    Orbassano, Torino, 10043

    Francesco Oliva, 3335613155, francesco.oliva@unito.it

    Recruiting

Other trials in Italy

About this study

Official title: Toll-Like Receptor Polymorphism, Antinuclear Antibodies and Beta-hemolytic Group A Streptococcus Infections in Attention-Deficit/Hyperactivity Disorder: an Observational Study

The aim of this observational cross-sectional study is to evaluate the streptococcal infection (clinical history, ASLO title and anti-DNAse title B) and autoimmunity (ABGA antibodies) in a sample of 100 adult patients diagnosed with ADHD (ie in patients in whom the disorder is permanent). Another objective will be to evaluate the frequency and types of genetic alterations of innate immunity (TLR polymorphisms, MyD88, IRAK-4) that can determine an infantile susceptibility to gram positive infections (ie S. pyogenes, S. pneumoniae, S. aureus) and the possible relationship between these elements, also in relation to comorbidity with other ABGA-related pathologies, to identify a possible pathogenetic immune mechanism of ADHD. Prevalence data will be obtained on an outpatient ADHD population for previous (history) and recent streptococcal infection (ASLO and Anti-DNAsiB), for the detection of ABGA and for the co-presence of other ABGA-related pathologies. By comparing the subgroups obtained by dividing the results on the basis of the positive infectious history, anti-streptococcus, autoantibody and comorbidity titers, it will be possible to assess whether the elevation of the ABGA titer is only linked to the previous/current infection ("infectious" group) or if there is a subpopulation of ADHD patients presenting pathological elevation of ABGA titers in the absence of infectious pictures ("immune" group). Furthermore, it is expected that the comparison of the descriptive polymorphisms TLR, MyD88 and IRAK-4 between the "infectious" and "immune" group may show a predisposition in subjects of the "immune" group.

Read the detailed description

Attention Deficit / Hyperactivity Disorder (ADHD) is the most widespread neurodevelopmental disorder (prevalence 3-7% in preschool age) and is characterized by persistent inattention and / or hyperactivity-impulsivity which results in significant impairment in at least two areas of operation (usually scholastic / working and relational) with consequent impact even on the child's self-esteem. It is estimated that one-third of children with ADHD continue to be affected in adulthood and that around one-third have remission of symptoms with persisting changes in functioning and development of psychiatric disorders in adulthood (eg anxiety disorders mood and personality). The pathogenetic model of ADHD is still poorly characterized: several biological, psychological and environmental causes have been identified that would seem to interact in a complex way in determining the pathology. Several studies have hypothesized and confirmed an association between streptococcal infections, increased titer of antibodies to the basal nuclei (ABGA), different neurological and psychiatric disorders (eg, Sydenham chorea, Tic Disorders, Obsessive-Compulsive Disorder) and ADHD. ADHD is diagnosed in 40% of autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) and Sydenham Korea and a temporal connection between onset / exacerbation of ADHD and pharyngeal streptococcal infection has been described in literature. High titers of anti-streptococcal antibodies and larger size of putamen and pallidum were found in ADHD patients. However, the permanence of symptoms ADHD at a distance from streptococcal infection has led to hypothesize, as already done for PANDAS and Sydenham Korea, a miminking mechanism with consequent cross-reactivity towards host tissues that would support an autoimmune disorder characterized by the production of ABGA.

According to some authors, therefore, ADHD and other ABGA-related neurological and psychiatric disorders (eg, Sydenham Korea, Tic Disorders, Obsessive-Compulsive Disorder) would be different phenotypic manifestations of a common immunological disorder affecting the nuclei of the base, triggered from group A beta-hemolytic streptococcus. The search for ABGA in ADHD patients with Tic Disorders and Obsessive-Compulsive Disorder has largely confirmed this hypothesis, however, the finding of ABGA titres in ADHD patients without comorbidities with other ABGA-related disorders is still controversial. A first study found no differences significant in terms of ABGA positivity frequency among ADHD patients without ABGA related disorders and controls while a more recent study conducted confirmed that children with ADHD without ABGA-related disorders are more frequently positive for ABGA than the control group (30% vs 4.8%; χ2 = 4.33; p = 0.04) and that, among these, those with Anti-Streptolysinic Title (ASLO) show significantly higher percentages of ABGA positivity (χ2 = 10.95; p <.001). On the other hand, greater susceptibility by ADHD patients to contracting streptococcal infections was confirmed by the finding of significantly higher titers of ASLO and anti-DNAse B in ADHD patients.

The predisposition to infections and the high familiarity of ADHD (90% of cases have at least one affected parent), suggest an immune pathogenetic mechanism based on a genetic predisposition.

Although several studies have established, in an inconclusive way, a relationship between ADHD and some regulatory genes, the major histocompatibility complex (MHC), such as HLA-DR4, HLA-DRB1 and C4B, to date no one has yet evaluated the role of Toll-type receptor (TLR) genes, which are more responsible for innate immunity, ie the recognition of pathogenic structural molecules. In particular, some variants of the TLR genes could affect the immune response to strepotococcus or other pathogens, favoring damage to the nuclei of the base which would in turn lead to ADHD symptoms. Recently, an association between susceptibility to serious or recurrent infections from group A beta-hemolytic streptococcus, Streptococcus pneumoniae, Haemophilus influenza and particular polymorphisms of TLR2, TLR4 and TLR9 has been demonstrated. The altered functioning consequent to these TLR polymorphisms could explain both the vulnerability to certain types of pathogens responsible for lesions to the central nervous system (among which the most studied so far is Group A beta-hemolytic streptococcus), whether the incongruous or excessive immune activation even in the absence of contact with pathogens producing autoantibodies against the nerve structures of the base nuclei.

Being tested
Antistreptolysin O Test, Anti-Deoxyribonuclease B, TLR, MyD88, IRAK-4 polymorphism, Anti-Basal Ganglia Antibody
Medical subject headings
Attention Deficit Disorder with Hyperactivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Antistreptolysin O TestDiagnostic test

    Also called ASO

    Test to evaluate of any histories of streptococcal infections

  • Anti-Deoxyribonuclease BDiagnostic test

    Also called Anti-DNase B

    Test to evaluate of any histories of streptococcal infections

  • TLR, MyD88, IRAK-4 polymorphismDiagnostic test

    Test to evaluate of the frequency and types of genetic alterations of innate immunity

  • Anti-Basal Ganglia AntibodyDiagnostic test

    Also called ABGA

    Test to evaluate the autoimmune component

Study groups in NCT04038073
Study groupRoleWhat they receive
ADHDAttention Deficit/Hyperactivity Disorder
Receives: Diagnostic Test: Antistreptolysin O Test; Diagnostic Test: Anti-Deoxyribonuclease B; Diagnostic Test: TLR, MyD88, IRAK-4 polymorphism; Diagnostic Test: Anti-Basal Ganglia Antibody

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measurement of Antistreptolysin O and Anti-Deoxyribonuclease B

    diagnostic blood sample test to measure streptococcal infections

    Measured: up to 1 year till the end of the study

  2. Measurement of TLR, MyD88, IRAK-4 polymorphism

    diagnostic blood sample test to measure genetic alterations of innate immunity

    Measured: up to 1 year till the end of the study

  3. Measurement of Anti-Basal Ganglia Antibody

    diagnostic blood sample test to assess the autoimmune component

    Measured: up to 1 year till the end of the study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jul 2019
  2. Study start3 Jun 2019
  3. Primary completion30 Jun 2020 (estimated)
  4. Study completion1 Dec 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04038073
Sponsor's protocol ID
ADHD_TLR
Acronym
TLR;
Status last verified
Mar 2020
First submitted
24 Jul 2019
Last updated
25 Mar 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Attention Deficit-Hyperactivity Disorder, run by University of Turin, Italy at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Francesco Oliva (3335613155, francesco.oliva@unito.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measurement of Antistreptolysin O and Anti-Deoxyribonuclease B (time frame: up to 1 year till the end of the study). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in